SILVER SPRING, Md.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions through its ongoing acquisition of the assets of SG Austria, today discussed the proprietary Cell-in-a-Box® technology, providing additional information about the science and technology behind the product.
